Ravnik Janez, Rowbottom Hojka
Department of Neurosurgery, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Diagnostics (Basel). 2024 Aug 15;14(16):1782. doi: 10.3390/diagnostics14161782.
Meningiomas represent approximately 40% of all primary tumors of the central nervous system (CNS) and, based on the latest World Health Organization (WHO) guidelines, are classified into three grades and fifteen subtypes. The optimal treatment comprises gross total tumor resection. The WHO grade and the extent of tumor resection assessed by the Simpson grading system are the most important predictors of recurrence. Atypical meningiomas, a grade 2 meningioma, which represent almost a fifth of all meningiomas, have a recurrence rate of around 50%. Currently, different histopathologic, cytogenetic, and molecular genetic alterations have been associated with different meningioma phenotypes; however, the data are insufficient to enable the development of specific treatment plans. The optimal treatment, in terms of adjuvant radiotherapy and postoperative systemic therapy in atypical meningiomas, remains controversial, with inconclusive evidence in the literature and existing studies. We review the recent literature to identify studies investigating relevant atypical meningioma biomarkers and their clinical application and effects on treatment options.
脑膜瘤约占中枢神经系统（CNS）所有原发性肿瘤的40%，根据世界卫生组织（WHO）的最新指南，可分为三个级别和十五个亚型。最佳治疗方法是肿瘤全切除。WHO分级以及通过辛普森分级系统评估的肿瘤切除程度是复发的最重要预测因素。非典型脑膜瘤属于2级脑膜瘤，占所有脑膜瘤的近五分之一，复发率约为50%。目前，不同的组织病理学、细胞遗传学和分子遗传学改变与不同的脑膜瘤表型相关；然而，数据不足以制定具体的治疗方案。对于非典型脑膜瘤的辅助放疗和术后全身治疗，最佳治疗方案仍存在争议，文献和现有研究中的证据尚无定论。我们回顾了近期文献，以确定研究相关非典型脑膜瘤生物标志物及其临床应用以及对治疗选择影响的研究。
